Dangerous Drugs
Acetaminophen
Accutane
Alli
Avandia
Baycol
Bextra
Celexa
Celebrex
Cardura
Diclofenax (Cataflam and Voltaren)
Digitek
Enbrel
Ephedra
Fentanyl (Duragesic)
Fosamax
Gadolinium (MRI Injection)
Glyburide
Hydroxycut
Ketek
Lamisil
Lexapro
Lipitor
Lotronex
Lymerix
Methadone
Neurontin
OrthoEvra
Oxycontin
Quinine
Pain Pumps
Paxil
Phenylpropanolamine
Prempro
Propulsid
ReNu Recall
Rezulin
Rituxan
Stadol
Serevent and Advair
Synthroid
Tequin
Topamax
Topical Anesthetic
Trasylol (Aprotinin)
Vaccination Litigation (VICP)
Viagra
Vioxx
Vytorin
Yaz
Zicam
Zithromax (Azithromycin)
Zyban
Dangerous Drugs
Dangerous Drugs
Dangerous Drugs





 

Dangerous Drugs
 

Propulsid

Propulsid Lawyer Helping Dangerous Drug Victims

Propulsid, a popular medication for severe gastroesophageal reflux disease (GERD) was pulled from the market as of July 14, 2000 after being linked to 341 reports of heart rhythm abnormalities. At least 80 deaths have been linked to Propulsid, also known as cisapride. This action by the manufacturer follows a January 24, 2000 warning by the Food and Drug Administration in which users were advised to be tested to determine whether heart damage had been sustained. Although Propulsid was not approved for use in babies, it is reported that its use in babies to treat reflux had become widespread, and some cardiac arhythmias and deaths resulted. Of the 80 deaths linked to Propulsid, 11 were babies. In one study of 58,000 premature babies' medical records, it was found that 20% were given Propulsid.

Most of the adverse events occurred in patients who had preexisting medical conditions or were taking other medications such as Biaxin, an antibiotic; Serzone, an antidepressant; Diflucan, Nizoral or Sporanox, antifungals; and Crixivan or Norvir, protease inhibitors. The drug is also given to patients with congestive heart failure, a history of ventricular arrhythmias, ischemic heart disease, multiple organ failure, chronic obstructive pulmonary disease, and advanced cancer.

The night time heartburn drug is manufactured by Janssen Pharmaceutica, a subsidiary of Johnson & Johnson. Propulsid was originally approved by the Food and Drug Administration in 1993 and was one of Johnson and Johnson's top selling drugs. The company is initiating a limited access program to make the drug available to patients who meet clearly defined eligibility criteria and for whom other therapies are not effective. Because of the risks associated with Propulsid and the many factors that need to be considered in prescribing it, the FDA has advised doctors to use the drug in patients who have not responded to other drug therapies or lifestyle modifications. Patients who are now using Propulsid are advised to consult with their physicians.

If you or loved one have been injured as a result of taking the above drug, you may have a valid claim. Call us now at 1-800-621-2020 or contact us.

Back To Dangerous Drugs

 
 
 
Melville Office
445 Broadhollow Road
Suite 205
Long Island, New York  11747
(800) 621-2020
Map & Directions
Garden City Office
1225 Franklin Avenue
Suite 325
Garden City, NY 11530
(800) 621-2020
Map & Directions

Buffalo Office:
2500 Main Place Tower
350 Main Street
Buffalo, New York 14202
(716) 854-2020
(800) 621-2020
Map & Directions

Rochester Office:
16 West Main Street
Powers Building, Suite 600
Rochester, New York 14614
(585) 454-2020
(800) 621-2020
Map & Directions

Grider Street Office:
451 Grider Street
Buffalo, New York 14215
(716) 854-2020
(800) 621-2020
Map & Directions

Manhattan Office:
405 Lexington Avenue
26th Floor, Chrysler Building
New York, New York  10174
(800) 621-2020
Maps & Directions